CT53518, a novel selective FLT3 antagonist for the sorted by
relevance

Admin07.08.2021

CT53518, a novel selective FLT3 antagonist for the

7101
Admin28.07.2021

CT53518, a novel selective FLT3 antagonist for the

6102
Admin30.09.2021

CT53518, a novel selective FLT3 antagonist for the

59010
Admin28.09.2021

CT53518, a novel selective FLT3 antagonist for the

7903
Admin16.07.2021

CT53518, a novel selective FLT3 antagonist for the

11010
Admin18.09.2021

CT53518, a novel selective FLT3 antagonist for the

5400
Admin19.07.2021

CT53518, a novel selective FLT3 antagonist for the

409
Admin06.10.2021

CT53518, a novel selective FLT3 antagonist for the

4209
Admin28.07.2021

CT53518, a novel selective FLT3 antagonist for the

6601
Admin18.08.2021

CT53518, a novel selective FLT3 antagonist for the

7505
Admin15.08.2021

CT53518, a novel selective FLT3 antagonist for the

4100
Admin06.10.2021

CT53518, a novel selective FLT3 antagonist for the

9008
Admin26.07.2021

CT53518, a novel selective FLT3 antagonist for the

704
Admin16.08.2021

(PDF) Phase 1 clinical results with tandutinib (MLN518), a

6006
Admin26.09.2021

Relation between inhibition of FLT3 phosphorylation in

4604
Admin01.08.2021

Distribution of KIT mutations in GISTs. | Download

1709
Admin14.07.2021

Flt Inhibition | Flt3 Mutation | Flt Inhibitor Review

8107
Admin01.10.2021

Tandutinib phase 1 experience: patient characteristics

7704
Admin19.08.2021

Tandutinib plasma concentration versus time profile for a

5106
Admin20.09.2021

Change in day-28 rate-corrected QT interval (QTc) from

1802
Admin01.08.2021

Risk stratification of primary GIST by mitotic index, size

8402